The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
BMS 754807 inhibits the reaction [palbociclib results in increased phosphorylation of AKT1 protein]; palbociclib promotes the reaction [idelalisib results in decreased phosphorylation of AKT1 protein]
[palbociclib results in increased susceptibility to idelalisib] which results in increased cleavage of CASP3 protein; palbociclib inhibits the reaction [Camptothecin results in increased activity of CASP3 protein]; palbociclib inhibits the reaction [Carboplatin results in increased activity of CASP3 protein]; palbociclib inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; palbociclib inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; palbociclib inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; palbociclib inhibits the reaction [Paclitaxel results in increased activity of CASP3 protein] palbociclib results in increased cleavage of CASP3 protein [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which affects the activity of CASP3 protein palbociclib results in decreased cleavage of CASP3 protein
palbociclib inhibits the reaction [Camptothecin results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Carboplatin results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Doxorubicin results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Paclitaxel results in increased activity of CASP7 protein] [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which affects the activity of CASP7 protein
palbociclib results in decreased expression of CCNA2 mRNA; palbociclib results in decreased expression of CCNA2 protein E2F2 protein inhibits the reaction [palbociclib results in decreased expression of CCNA2 protein]; palbociclib inhibits the reaction [Doxorubicin results in increased expression of CCNA2 protein]; palbociclib inhibits the reaction [RBL1 protein binds to CCNA2 promoter]; palbociclib promotes the reaction [RB1 protein binds to CCNA2 promoter]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of CCNA2 protein]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to CCNA2 promoter]]; RB1 protein affects the reaction [palbociclib results in decreased expression of CCNA2 protein]
CCND1 gene results in decreased susceptibility to palbociclib [CDKN2A gene mutant form results in increased expression of CCND1 protein] which results in increased susceptibility to palbociclib palbociclib results in increased expression of CCND1 protein [BMS 754807 co-treated with palbociclib] results in increased expression of CCND1 protein; Doxorubicin inhibits the reaction [palbociclib results in increased expression of CCND1 protein]; palbociclib inhibits the reaction [[CDK4 protein binds to CCND1 protein] which results in increased phosphorylation of SHOX2 protein]; palbociclib promotes the reaction [CCND1 protein binds to CDKN1B protein binds to CDK4 protein]; palbociclib promotes the reaction [CDK4 protein binds to CCND1 protein]
palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of MEF2D protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RB1 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RBL2 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of SENP3 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of ZEB1 protein] [CDKN2A gene mutant form results in increased expression of CCND3 protein] which results in increased susceptibility to palbociclib palbociclib results in increased expression of CCND3 protein
CCNE1 protein results in decreased susceptibility to palbociclib palbociclib results in decreased expression of CCNE1 protein palbociclib results in increased expression of CCNE1 protein
2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [palbociclib results in increased expression of CDH2 protein]
palbociclib results in decreased activity of CDK2 protein palbociclib results in increased phosphorylation of and results in increased expression of CDK2 protein palbociclib results in decreased phosphorylation of CDK2 protein palbociclib results in decreased expression of CDK2 protein
CDK4 protein results in decreased susceptibility to palbociclib palbociclib results in decreased activity of CDK4 protein [CDKN2A gene mutant form results in increased expression of CDK4 protein] which results in increased susceptibility to palbociclib palbociclib results in increased expression of CDK4 protein palbociclib inhibits the reaction [[CDK4 protein binds to CCND1 protein] which results in increased phosphorylation of SHOX2 protein]; palbociclib inhibits the reaction [CDC37 protein binds to CDK4 protein]; palbociclib promotes the reaction [CCND1 protein binds to CDKN1B protein binds to CDK4 protein]; palbociclib promotes the reaction [CDK4 protein binds to CCND1 protein] CDK4 protein results in increased susceptibility to palbociclib
palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of MEF2D protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RB1 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RBL2 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of SENP3 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of ZEB1 protein]; palbociclib inhibits the reaction [CDC37 protein binds to CDK6 protein] palbociclib results in increased expression of CDK6 protein [CDKN2A gene mutant form results in increased expression of CDK6 protein] which results in increased susceptibility to palbociclib
palbociclib promotes the reaction [CCND1 protein binds to CDKN1B protein binds to CDK4 protein] palbociclib results in increased expression of CDKN1B mRNA; palbociclib results in increased expression of CDKN1B protein palbociclib results in decreased expression of CDKN1B protein
CDKN2A gene modified form affects the susceptibility to palbociclib; CDKN2A gene mutant form affects the susceptibility to palbociclib; CDKN2A protein affects the susceptibility to palbociclib CDKN2A gene mutant form results in increased susceptibility to palbociclib [CDKN2A gene mutant form results in increased expression of CCND1 protein] which results in increased susceptibility to palbociclib; [CDKN2A gene mutant form results in increased expression of CCND2 protein] which results in increased susceptibility to palbociclib; [CDKN2A gene mutant form results in increased expression of CCND3 protein] which results in increased susceptibility to palbociclib; [CDKN2A gene mutant form results in increased expression of CDK4 protein] which results in increased susceptibility to palbociclib; [CDKN2A gene mutant form results in increased expression of CDK6 protein] which results in increased susceptibility to palbociclib; [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which affects the activity of CASP3 protein; [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which affects the activity of CASP7 protein; [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which results in decreased phosphorylation of RB1 protein CDKN2A protein results in decreased susceptibility to palbociclib [CDKN2A protein co-treated with CDKN2C protein] affects the susceptibility to palbociclib
palbociclib results in increased expression of CDKN2B protein 2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [palbociclib results in increased expression of CDKN2B protein] CDKN2B protein results in decreased susceptibility to palbociclib
2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [palbociclib results in increased expression of CTNNB1 protein]
palbociclib inhibits the reaction [Doxorubicin results in increased expression of E2F1 protein]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of E2F1 protein]]
E2F2 protein inhibits the reaction [palbociclib results in decreased expression of CCNA2 protein]; E2F2 protein inhibits the reaction [palbociclib results in decreased expression of RNR2 protein]; E2F2 protein inhibits the reaction [palbociclib results in decreased phosphorylation of RB1 protein] palbociclib results in decreased expression of E2F2 mRNA
palbociclib results in decreased expression of FLT3 mRNA; palbociclib results in decreased expression of FLT3 protein FLT3 protein affects the susceptibility to palbociclib palbociclib results in decreased phosphorylation of FLT3 protein [FLT3 protein affects the susceptibility to palbociclib] which results in decreased expression of FLT3 protein
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [palbociclib results in decreased expression of FOXM1 protein]; CDH1 protein affects the reaction [palbociclib results in decreased expression of FOXM1 protein]; palbociclib results in decreased expression of and results in decreased activity of FOXM1 protein palbociclib results in decreased expression of FOXM1 mRNA
Doxorubicin inhibits the reaction [palbociclib results in decreased phosphorylation of H2AX protein]; palbociclib inhibits the reaction [Camptothecin results in increased expression of H2AX protein]; palbociclib inhibits the reaction [Carboplatin results in increased expression of H2AX protein]; palbociclib inhibits the reaction [Doxorubicin results in increased expression of H2AX protein]; palbociclib inhibits the reaction [Etoposide results in increased expression of H2AX protein]; palbociclib inhibits the reaction [Paclitaxel results in increased expression of H2AX protein]; RB1 protein affects the reaction [palbociclib results in decreased phosphorylation of H2AX protein]
RB1 protein affects the reaction [palbociclib results in decreased expression of MCM7 protein] palbociclib results in decreased expression of MCM7 mRNA; palbociclib results in decreased expression of MCM7 protein
Doxorubicin promotes the reaction [palbociclib results in decreased expression of MKI67 protein]; RB1 protein affects the reaction [palbociclib results in decreased expression of MKI67 protein]
[palbociclib results in increased susceptibility to idelalisib] which results in increased cleavage of PARP1 protein; palbociclib inhibits the reaction [Doxorubicin results in increased cleavage of PARP1 protein]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased cleavage of PARP1 protein]]
palbociclib results in decreased expression of PLK1 mRNA palbociclib inhibits the reaction [RBL1 protein binds to PLK1 promoter]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to PLK1 promoter]]
palbociclib affects the phosphorylation of RB1 protein palbociclib results in decreased expression of RB1 mRNA; palbociclib results in decreased expression of RB1 protein RB1 protein results in increased susceptibility to palbociclib [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which results in decreased phosphorylation of RB1 protein RB1 protein affects the susceptibility to palbociclib BMS 754807 promotes the reaction [palbociclib results in decreased phosphorylation of RB1 protein]; E2F2 protein inhibits the reaction [palbociclib results in decreased phosphorylation of RB1 protein]; palbociclib affects the reaction [RB1 mutant form results in increased expression of RBL2 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RB1 protein]; palbociclib inhibits the reaction [[PDGFB protein binds to PDGFB protein] inhibits the reaction [RB1 protein binds to SP1 protein]]; palbociclib inhibits the reaction [bis(4-hydroxyphenyl)sulfone results in increased phosphorylation of RB1 protein]; palbociclib promotes the reaction [RB1 protein binds to CCNA2 promoter]; palbociclib promotes the reaction [RB1 protein binds to SP1 protein]; palbociclib results in decreased phosphorylation of and results in decreased expression of RB1 protein; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased cleavage of PARP1 protein]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of CCNA2 protein]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of E2F1 protein]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of TOP2A protein]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to CCNA2 promoter]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to PLK1 promoter]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to RNR2 promoter]]; RB1 protein affects the reaction [palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]]; RB1 protein affects the reaction [palbociclib results in decreased expression of CCNA2 protein]; RB1 protein affects the reaction [palbociclib results in decreased expression of MCM7 protein]; RB1 protein affects the reaction [palbociclib results in decreased expression of MKI67 protein]; RB1 protein affects the reaction [palbociclib results in decreased expression of RBL1 protein]; RB1 protein affects the reaction [palbociclib results in decreased phosphorylation of H2AX protein]; RB1 protein affects the reaction [palbociclib results in decreased phosphorylation of RB1 protein] RB1 gene mutant form results in decreased susceptibility to palbociclib; RB1 mutant form results in decreased susceptibility to palbociclib RB1 protein affects the reaction palbociclib palbociclib results in increased phosphorylation of RB1 protein
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [palbociclib results in decreased expression of RBL1 protein]; palbociclib inhibits the reaction [RBL1 protein binds to CCNA2 promoter]; palbociclib inhibits the reaction [RBL1 protein binds to PLK1 promoter]; palbociclib inhibits the reaction [RBL1 protein binds to RNR2 promoter]; palbociclib promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of RBL1 protein]; palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]; palbociclib results in decreased phosphorylation of and results in decreased expression of RBL1 protein; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to CCNA2 promoter]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to PLK1 promoter]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to RNR2 promoter]]; RB1 protein affects the reaction [palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]]; RB1 protein affects the reaction [palbociclib results in decreased expression of RBL1 protein] palbociclib results in decreased expression of RBL1 mRNA; palbociclib results in decreased expression of RBL1 protein
palbociclib affects the reaction [RB1 mutant form results in increased expression of RBL2 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RBL2 protein]; palbociclib results in decreased phosphorylation of and results in increased expression of RBL2 protein; palbociclib results in increased expression of and results in increased stability of RBL2 protein palbociclib results in decreased phosphorylation of RBL2 protein
2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [palbociclib results in increased expression of SNAI2 protein]
palbociclib inhibits the reaction [[PDGFB protein binds to PDGFB protein] inhibits the reaction [RB1 protein binds to SP1 protein]]; palbociclib promotes the reaction [RB1 protein binds to SP1 protein]
palbociclib analog results in decreased expression of TK1 mRNA; palbociclib results in decreased expression of TK1 mRNA; palbociclib results in decreased expression of TK1 protein
palbociclib analog results in decreased expression of TOP2A mRNA; palbociclib results in decreased expression of TOP2A mRNA; palbociclib results in decreased expression of TOP2A protein palbociclib inhibits the reaction [Doxorubicin results in increased expression of TOP2A protein]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of TOP2A protein]]
pevonedistat results in increased cleavage of and results in increased activity of CASP3 protein; Tretinoin promotes the reaction [pevonedistat results in increased cleavage of and results in increased activity of CASP3 protein]
pevonedistat results in increased abundance of JUN protein Tretinoin promotes the reaction [pevonedistat results in increased abundance of JUN protein]
pevonedistat results in increased cleavage of PARP1 protein pevonedistat results in increased cleavage of and results in increased activity of PARP1 protein; Tretinoin promotes the reaction [pevonedistat results in increased cleavage of and results in increased activity of PARP1 protein]
pevonedistat results in increased abundance of PMAIP1 protein pevonedistat affects the expression of PMAIP1 mRNA Tretinoin promotes the reaction [pevonedistat results in increased abundance of PMAIP1 protein]
browse the term
